Reconstitution of Herpes Simplex Virus-Specific T Cell Immunity in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy

Ramaswamy, Meghna; Waters, Anele; Smith, Colette; Hainsworth, Emma; Hardy, Gareth; Johnson, Margaret; Ainsworth, Jonathan; Phillips, Andrew; Geretti, Anna Maria
February 2007
Journal of Infectious Diseases;2/1/2007, Vol. 195 Issue 3, p410
Academic Journal
Production of herpes simplex virus (HSV)-specific interferon-g by peripheral-blood mononuclear cells (PBMCs) of HSV-seropositive healthy donors and human immunodeficiency virus-infected persons was determined by use of ELISPOT. The mean ± SD number of spot-forming cells/106 PBMCs was 314 ± 74 in 11 healthy donors, 360 ± 69 in 3 long-term nonprogressors (LTNPs), 186 ± 52 in 9 newly diagnosed patients, and 181 ± 59 in 33 patients who were receiving highly active antiretroviral therapy (HAART) for a median period of 30 months (range, 1-109 months). In 9 patients monitored prospectively while receiving virologically and immunologically successful first-line HAART, the number of spot-forming cells increased by 5.6/month (95% confidence interval, 1.2-9.9 [P = .01]) and 21.3/100 CD4 cells/mm³ gained (95% confidence interval, 13.8-28.7 [P < .0001]). Responses were correlated with LTNP status and CD4 cell count.


Related Articles

  • Comparing Effects of BK Virus Agnoprotein and Herpes Simplex-1 ICP47 on MHC-I and MHC-II Expression. Cioni, Michela; Mittelholzer, Christian; Wernli, Marion; Hirsch, Hans H. // Clinical & Developmental Immunology;2013, p1 

    Background. Among human polyomaviruses, only BK virus (BKV) and JC virus (JCV) encode an agnoprotein upstream of VP1 on the viral late transcript. BKV agnoprotein is abundantly expressed late in the viral life cycle, but specific cellular and humoral immune responses are low or absent. We...

  • Efficacy and Safety of Valacyclovir for the Suppression and Episodic Treatment of Herpes Simplex Virus in Patients with HIV. Warren, Terri; Harris, Julia; Brennan, Clare A. // Clinical Infectious Diseases;10/15/2004 Supplement, Vol. 39, pS258 

    The prevalence and predisposing factors of thrombotic microangiopathy (TMA) in the era of highly active antiretroviral therapy (HAART) were evaluated among patients in the Collaborations in Human Immunodeficiency Virus (HIV) Outcomes Research/US cohort. Of 6022 patients, 17 (0.3%) had TMA, with...

  • Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Conant, M. A.; Schacker, T. W.; Murphy, R. L.; Gold, J.; Crutchfield, L. T.; Crooks, R. J.; International Valaciclovir HSV Study Group // International Journal of STD & AIDS;Jan2002, Vol. 13 Issue 1, p12 

    Our objective was to evaluate valaciclovir for anogenital herpes in HIV-infected individuals using 2 controlled trials conducted before highly active antiretroviral therapy (HAART) was used. In Study 1, 1062 patients (CD4+ > or = 100 cells/mm(3)) received suppressive valaciclovir or aciclovir...

  • Phase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre-and Post-tumor Resection for Recurrent GBM. Markert, James M.; Liechty, Peter G.; Wenquan Wang; Gaston, Shanna; Braz, Eunice; Karrasch, Matthias; Nabors, Louis B.; Markiewicz, Michael; Lakeman, Alfred D.; Palmer, Cheryl A.; Parker, Jacqueline N.; Whitley, Richard J.; Gillespie, George Y. // Molecular Therapy;Jan2009, Vol. 17 Issue 1, p199 

    We have previously demonstrated safety of G207, a doubly mutated (deletion of both γ134.5 loci, insertional inactivation of UL39) herpes simplex virus (HSV) for patients stereotactically inoculated in enhancing portions of recurrent malignant gliomas. We have now determined safety of two...

  • The effect of valacyclovir on HIV and HSV-2 in HIV-infected persons on antiretroviral therapy with previously unrecognised HSV-2. Van Wagoner, Nicholas; Geisler, William M; Bachmann, Laura H; Hook, Edward W // International Journal of STD & AIDS;Jul2015, Vol. 26 Issue 8, p574 

    In the absence of antiretroviral therapy, valacyclovir may reduce HIV viral load and increase CD4+ T-lymphocyte count. We sought to evaluate the impact of valacyclovir on HIV and HSV-2 in co-infected patients receiving antiretroviral therapy with previously unrecognised HSV-2 infection. A...

  • A New Class of Dual-Targeted Antivirals: Monophosphorylated Acyclovir Prodrug Derivatives Suppress Both Human Immunodeficiency Virus Type 1 and Herpes Simplex Virus Type 2. Vanpouille, Christophe; Lisco, Andrea; Derudas, Marco; Saba, Elisa; Grivel, Jean-Charles; Brichacek, Beda; Scrimieri, Francesca; Schinazi, Raymond; Schols, Dominique; McGuigan, Christopher; Balzarini, Jan; Margolis, Leonid // Journal of Infectious Diseases;2/15/2010, Vol. 201 Issue 4, p635 

    Background. Human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 2 (HSV-2) are responsible for 2 intersecting epidemics in which the disease caused by 1 virus facilitates the transmission of and pathogenesis by the other. Therefore, suppression of one virus infection will...

  • Experimental study on antiviral activity of silicone oil in vitro. Hua Yan; Jun Li // Graefe's Archive of Clinical & Experimental Ophthalmology;Sep2008, Vol. 246 Issue 9, p1285 

    Abstract Objective  To study the antiviral activity of silicone oil against herpes simplex virus-1 (HSV-1) in vitro. Methods  (1) TCID50 (Tissue culture infectious dose 50% endpoint) of HSV-1 was titrated. (2) The Hela cells were placed in a 96-well plate. (3) The virus was...

  • Antivirals Reduce the Formation of Key Alzheimer's Disease Molecules in Cell Cultures Acutely Infected with Herpes Simplex Virus Type 1. Wozniak, Matthew A.; Frost, Alison L.; Preston, Chris M.; Itzhaki, Ruth F. // PLoS ONE;2011, Vol. 6 Issue 10, p1 

    Alzheimer's disease (AD) afflicts around 20 million people worldwide and so there is an urgent need for effective treatment. Our research showing that herpes simplex virus type 1 (HSV1) is a risk factor for AD for the brains of people who possess a specific genetic factor and that the virus...

  • Type I Interferon Production Is Profoundly and Transiently Impaired in Primary HIV-1 Infection. Kamga, Isabelle; Kahi, Sandrine; Develioglu, Leyla; Lichtner, Miriam; Marañón, Concepción; Deveau, Christiane; Meyer, Laurence; Goujard, Cécile; Lebon, Pierre; Sinet, Martine; Hosmalin, Anne // Journal of Infectious Diseases;7/15/2005, Vol. 192 Issue 2, p303 

    Background. Successful immunological control of human immunodeficiency virus (HIV) infection is achieved only in rare individuals. Plasmacytoid dendritic cells (DCs) are mostly responsible for the production of strong antiviral factors-that is, type I interferons (IFNs)-in response to viruses....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics